A gene expression profile test improved identification of the metastasis risk in patients with melanoma who underwent sentinel lymph node biopsy, according to recently published study results.
MRV Research
Study Shows Castle Biosciences’ Noninvasive Skin Melanoma Gene Test Improves Accuracy of Sentinel Lymph Node Biopsy in Predicting Metastasis
Castle Biosciences Inc. today announced the publication of a clinical study showing that its gene expression profile (GEP) test for cutaneous (skin) melanoma improved the prognostic accuracy of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of their cancer spreading. The GEP test was able to identify as high risk a significant number of patients whose sentinel lymph node biopsy results did not indicate any increased risk but who subsequently developed metastatic disease.
Pioneering Blood-Based Biomarker Strategy Allows Early Cancer Detection in Mice
Researchers at Stanford University School of Medicine in California have recently revealed a new strategy for cancer detection via the use of blood-based biomarkers. The study is entitled “Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker” and was published in the journal Proceedings of the National Academy of Sciences.
Gene Alterations in Melanoma May Predict Immunotherapy Outcomes
Among melanoma patients who were treated with immunotherapies, those whose tumors had mutations in the gene NRAS had better response and treatment outcomes than those whose tumors did not have NRAS mutations, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research